|
- FDA approves twice-a-year injection for HIV prevention - CNN
Gilead Sciences, maker of the drug, announced that a twice-a-year injection of lenacapavir has been approved in the United States for HIV prevention under the brand name Yeztugo
- Regulators Approve Lenacapavir for H. I. V. Prevention - The . . .
In the United States, more than 39,000 people contracted H I V in 2023 Every newly infected person incurs about $1 1 million in medical care over his or her lifetime, Daniel O’Day, Gilead’s
- FDA approves lenacapavir as a twice-a-year shot to prevent . . .
WASHINGTON (AP) — The U S has approved the world’s only twice-a-year shot to prevent HIV, maker Gilead Sciences announced Wednesday It’s the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U S and abroad will get access to the powerful new option
- HIV prevention drug lenacapavir approved by FDA as twice . . .
What to know about the Trump administration's move to cut HIV vaccine research funding 02:33 The U S Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to
- FDA approves new twice-yearly HIV shot. What to know
The Food and Drug Administration on Wednesday approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections Gilead did
- Yeztugo Lenacapavir Is Now the First and Only FDA Approved . . .
FOSTER CITY, Calif --(BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) today announced that the U S Food and Drug Administration (FDA) has approved Yeztugo ® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice
- HIV prevention drug hailed as a breakthrough gets FDA approval
A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of HIV
|
|
|